Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1 nucleocapsid protein by Gamba, Elia et al.
Original Citation:
Identification of novel 2-benzoxazolinone derivatives with specific inhibitory activity against the HIV-1
nucleocapsid protein
Elsevier
Publisher:
Published version:
DOI:
Terms of use:
Open Access
(Article begins on next page)
This article is made available under terms and conditions applicable to Open Access Guidelines, as described at
http://www.unipd.it/download/file/fid/55401 (Italian only)
Availability:
This version is available at: 11577/3254121 since: 2018-01-10T13:29:45Z
10.1016/j.ejmech.2017.12.073
Università degli Studi di Padova
Padua Research Archive - Institutional Repository
 1 
Identification of novel 2-benzoxazolinone 
derivatives with specific inhibitory activity against 
the HIV-1 nucleocapsid protein 
Elia Gambaa, ‡, Mattia Morib, ‡, Lesia Kovalenkoc, d, Alessia Gianninie, Alice Sosica, Francesco 
Saladinie, Dan Fabrisf, Yves Mélyc, Barbara Gattoa*, Maurizio Bottab 
a Dipartimento di Scienze del Farmaco, Università di Padova, via Marzolo 5, 35131 Padova, 
Italy 
b Dipartimento di Biotecnologie, Chimica e Farmacia, Università degli Studi di Siena, via A. 
Moro, 53100 Siena, Italy 
c Laboratoire de Biophotonique et Pharmacologie, UMR 7213 CNRS, Faculté de Pharmacie, 
Université de Strasbourg, 67401 Illkirch, France  
d Department of Chemistry, Kyiv National Taras Shevchenko University, 01033 Kyiv, Ukraine 
e Dipartimento Biotecnologie Mediche, Università degli Studi di Siena, viale M. Bracci, 53100 
Siena, Italy 
f The RNA Institute and Department of Chemistry, State University of New York, 1400 
Washington Avenue, Albany, New York 12222, United States  
 
AUTHOR INFORMATION 
Corresponding author 
*Email: barbara.gatto@unipd.it. Phone: +39 049 8275717. Fax: +39 049 8275366  
Author contributions 
‡E.G. and M.M. contributed equally to the paper and are both first authors. 
 2 
ABSTRACT 
In this report, we present a new benzoxazole derivative endowed with inhibitory activity against 
the HIV-1 nucleocapsid protein (NC). NC is a 55-residue basic protein with nucleic acid 
chaperone properties, which has emerged as a novel and potential pharmacological target against 
HIV-1. In the pursuit of novel NC-inhibitor chemotypes, we performed virtual screening and in 
vitro biological evaluation of a large library of chemical entities. We found that compounds 
sharing a benzoxazolinone moiety displayed putative inhibitory properties, which we further 
investigated by considering a series of chemical analogues. This approach provided valuable 
information on the structure-activity relationships of these compounds and, in the process, 
demonstrated that their anti-NC activity could be finely tuned by the addition of specific 
substituents to the initial benzoxazolinone scaffold. This study represents the starting point for 
the possible development of a new class of antiretroviral agents targeting the HIV-1 NC protein.  
 
KEYWORDS 
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ABBREVIATIONS 
NC, nucleocapsid protein; TAR, trans-activation response element; cTAR, trans-activation 
response element complementary sequence; dTAR, trans-activation response element 
(deoxyribonucleotides sequence); DFT, density functional theory; Dabcyl, 4-(4’-
dimethylaminophenylazo) benzoic acid; NAME, nucleocapsid annealing mediated 
electrophoresis; RLU, relative luminescence units; IC50, half-maximum inhibitory concentration; 
TD50, half-maximum toxic dose; CI, confidence intervals; SI, selectivity index; ARP, AIDS 
research program; DMSO, dimethyl sulfoxide 
 
INTRODUCTION 
The absence of an effective vaccine and the emergence of drug resistance represent major 
challenges in the long-term treatment of the infections by human immunodeficiency virus type 1 
(HIV-1) [1]. Current pharmacological strategies comprise combinations of drugs that are active 
against a variety of viral targets, such as protease, reverse transcriptase, integrase, and viral entry 
[2]. The development of new classes of antiretrovirals active against different types of targets 
could represent a very important step towards containing the costs and limiting the incidence of 
drug resistance associated with the long-term nature of HIV treatment [2]. For this reason, 
renewed efforts are being directed towards identifying small molecules capable of interfering 
with other HIV-1 targets or host proteins. A possible new target is represented by the 
nucleocapsid protein (NC), a small viral protein endowed with nucleic acid chaperone properties, 
which is essential to viral replication. For over two decades, NC has been the object of intense 
interest due to its involvement in different steps of the replication cycle and its high degree of 
structure conservation among different viral strains [3]. In particular, NC mediates the 
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transcription initiation and transfer of minus and plus DNA strands, which are essential steps of 
the reverse transcription process [4]. It plays also essential roles in genome recognition and 
packaging, which lead to the assembly and encapsidation of new viral particles [5]. These 
biological functions rely on highly conserved zinc finger (ZF) domains, which can readily lose 
activity upon single-point mutation, leading to significant decrease of viral infectivity [6]. Based 
on these multifaceted activities, inhibition of NC could simultaneously affect multiple processes. 
This scenario would greatly reduce the possibility of producing drug resistant strains, which 
would require multiple concomitant mutations. 
 Over the years, different strategies have been proposed to achieve the effective inhibition 
of the biological functions of NC. Possible zinc-ejecting agents have been investigated for their 
ability to sequester the divalent cation, or interfere with metal coordination by the ZF residues [7, 
8]. However, a typically low specificity for retroviral versus mammalian ZF structures has 
thwarted further progress in this direction. Additional strategies have been explored, which 
targeted the nucleic acid substrates of NC, rather than the protein itself. These efforts have been 
met with limited results because only few molecules showed to inhibit the viral replication by 
targeting the putative target in cell model systems [9-11]. A more promising alternative consists 
of possible competitive inhibitors that may be capable of interfering with the binding of NC to 
typical nucleic acid substrates [3]. Indeed, it has been shown that the hydrophobic pocket, which 
forms when the ZF domains are brought close together, for example, by interacting with an 
exposed guanine nucleobase on cognate nucleic acid substrates, can establish stable interactions 
with small molecule ligands [12-14]. Although such compounds have been touted as possible 
modulators of NC-nucleic acid interactions, no drug candidate has emerged thus far. The 
development of actual antivirals with this mechanism of action has been hampered by the high 
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flexibility of the protein and the absence of a clinically validated inhibitor that may serve as a 
possible template. For these reasons, we set out to identify possible chemotypes that may 
combine selective NC-binding activity with the ability to interfere with its specific interactions 
with nucleic acid substrates, also providing antiviral effects in cell model systems.   
In previous work, we utilized virtual screening techniques to explore a chemical library 
comprising more than 300,000 compounds, which we hoped would contain the sought-after 
chemotypes for NC inhibition [15]. The hydrophobic pocket between the ZF domains was 
employed in docking operations that identified ten compounds with excellent structural 
similarity with the interaction engaged by guanine nucleobase. A systematic evaluation of their 
in vitro antiviral activity and NC-binding properties revealed that two compounds possessed the 
favorable characteristics to compete for guanine binding to the ZF domain of NC [15]. In this 
work, we further expanded the virtual screening to a chemical database of approximately 3.5 
million molecules. This operation identified thirty-five possible binders. Interestingly, we found 
structural similarities with those identified in the previous docking study [15]. Preliminary 
activity evaluation focused our attention on a promising 2-benzoxazolinone scaffold that was 
proven capable of inhibiting NC at low M concentrations. To support further development, we 
performed biophysical studies aimed at elucidating its possible mechanism of action. We also 
evaluated a series of chemical analogues to obtain valuable insights into the structural activity 
relationships (SARs). This report describes the results and discusses a possible path toward the 
development of a new class of competitive NC inhibitors capable of interfering with the nucleic 
acid binding properties of NC.  
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RESULTS AND DISCUSSION 
Combining virtual screening and in vitro activity evaluation to identify potential NC 
inhibitors. We implemented a combined approach for the identification of potential NC 
inhibitors, which utilized the virtual screening of a large chemical library to identify putative 
chemotypes, followed by in vitro assessment of their inhibitory activity on the nucleic acid 
binding and chaperone properties of NC. Previous studies have revealed that any small molecule 
ligand capable of interfering with NC nucleic acids binding activity should preferentially 
establish H-bonding interactions with Phe16, Lys33, Gly35, Trp37 and Met46, as well as π-
stacking interactions with Trp37 [12]. Based on these key structural determinants, our virtual 
screening aimed at evaluating the ability of the various molecules to establish specific contacts 
with the conserved structural domains of NC. For each compound in the initial library, the 
binding mode and theoretical affinity within the hydrophobic site of NC, were estimated in silico 
by a suitable docking and scoring function, respectively. The putative receptors were generated 
from available experimental structures of NC in complex with pertinent RNA and DNA 
substrates, such as the HIV-1 SL3 [16] and PBS(-) [17], which were further refined by 
computational approaches [18]. The nucleic acid moieties were then removed to obtain an empty 
binding pocket used for docking experiments. This process was also completed on the NMR 
structure of NC in complex with the reference compound cmpd3 (Supplementary materials, 
Figure S1) [19], which was included as ligand-binding NC structure to increase the reliability of 
the virtual screening operation.  
The set of putative ligands consisted of the MolPort database 
(https://www.molport.com/shop/index) of commercially available compounds (about 3.5 million 
molecules in stock at the time of this study), which were evaluated according to different criteria, 
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such as the visual inspection of the predicted binding mode and interaction with the key residues, 
the estimated theoretical affinity for the protein, and the chemical diversity between the most 
promising hit candidates in order to explore the largest set of possible different chemical 
scaffolds. Each molecule was docked to the hydrophobic pocket of NC in each of the three 
conformational states obtained above. The theoretical affinity was estimated by the Chemgauss4 
function of the FRED docking program [20, 21]. Docking results were elaborated according to a 
consensus rank-by-rank strategy that averaged the ranking position of each compound in each 
NC receptor structure and generated a consensus ranking list. The top 5% hit candidates were 
then selected for further processing. The chemical diversity of this selection was enhanced by a 
clustering approach based on a combination of molecular fingerprints and substructures, as 
described by Stahl et al. and already used with success in prior studies [22, 23]. Based on these 
criteria, the screening led to the identification of molecule 1 to 35 (Supplementary materials, 
Figure S1), which were subjected to experimental activity evaluations.  
The NC-inhibitory activity of molecule 1–35 was assessed by using the Nucleocapsid 
Annealing Mediated Electrophoresis assay (NAME, see Materials and Methods) [24], which 
provided a measure of their ability to interfere with the NC-mediated annealing of two 
complementary oligonucleotides. The substrates employed in the assay consisted of 
oligonucleotides mimicking the trans-activation response element (TAR29) and its 
complementary DNA (cTAR29) counterpart, whose annealing replicates an early obligatory step 
of the HIV-1 reverse transcription process [4]. Gel electrophoresis was then employed to 
quantify the formation of the TAR29/cTAR29 duplex mediated by NC, as described in previous 
studies [24]. Due to solubility problems, thirty of the thirty-five compounds identified by the 
virtual screening were submitted to this assay (Supplementary materials, Table S1). The results 
 8 
were initially ranked according to the intensity of the band corresponding to the annealed 
construct, which provided an effective reading of the inhibitory activity by direct visual 
inspection. The results indicated that compound N-(2,4-dimethylphenyl)-2-oxo-2,3-dihydro-1,3-
benzoxazole-5-sulfonamide (5) possessed the best inhibitory activity in the series 
(Supplementary materials, Table S1), as highlighted by a clear dose-dependent decrease of the 
TAR29/cTAR29 duplex accompanied by a corresponding increase of its monomeric components 
(Figure 1).  
 
Figure 1. NC-inhibitory activity of compound 5 assessed by using the Nucleocapsid Annealing Mediated 
Electrophoresis (NAME) assay [24]. Briefly, an 8 µM aliquot of NC(12-55) was pre-incubated with increasing 
concentrations of 5 at room temperature for 15 minutes. Each sample was then added with 1 µM each of TAR29 and 
cTAR29, incubated at room temperature for 15 minutes, and then analyzed by non-denaturing polyacrylamide gel 
electrophoresis (see Materials and Methods for details). Control samples were also included on the left side of the 
gel, which corresponded to monomeric TAR29 and cTAR29 species, as well as TAR29/cTAR29 duplex (Dup) 
obtained by thermal re-folding. 
 
Although no complete inhibition was observed within the range of concentrations 
explored in these experiments, this compound possessed a 2-benzoxazolinone moiety of a hit 
compound identified in a previous study (cmpd8) [15], as well as the 2-oxindole substructure 
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present in the reference NC inhibitor cmpd3 (Figure 2) [19]. These uncanny similarities 
convinced us that compound 5 might have captured putative structural determinants of NC-
inhibitory activity, which might be finely tuned with proper chemical decoration to achieve the 
desired inhibition levels. Based on these considerations, we undertook a second virtual screening 
that searched specifically for compounds containing the 2-benzoxazolinone molecular scaffold.  
 
 Optimization of benzoxazolinone derivatives improved their NC-inhibitory activity. The 
second round of screening involved building a virtual library of commercially available 
compounds containing the 2-oxindole substructure. This substructure was selected as inclusive of 
a number of benzo-fused heterocycles having different atom types at position 3 (i.e. O, C, N, S), 
which was shown by molecular modeling and NMR spectroscopy not to participate directly in 
binding to the protein [15, 19]. More specifically, the latest available version of the ZINC 
database [25] was explored by using the FILTER algorithm (OpenEye, Santa Fe, NM), which 
identified ~5,100 stock compounds bearing the 2-oxindole substructure. This initial group of 
putative ligands was docked by following the same criteria to the receptor structures described 
above. The process yielded a series of nineteen analogues of compound 5 (named 5-01 to 5-19, 
Figure 2), which included both benzoxazolinone and benzimidazolinone structures that were 
able to fit the NC hydrophobic pocket and establish H-bonds with key NC residues [3, 12, 14, 
15]. These compounds were further evaluated for their NC inhibition activity.  
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Figure 2. Chemical structures of the analogues of hit compound 5 selected by the second round of virtual screening. 
The structures of the parent hit compound 5 is highlighted at the top of the figure together with the reference 
compound cmpd3 [19] and the benzoxazole inhibitor identified in a previous study (cmpd8) [15]. 
 
Among the analogues tested by the NAME assay, five compounds displayed detectable 
inhibition of the NC chaperone activity (Table 1). The representative data shown in Figure 3 
demonstrated that the compound N-(1H-indazol-5-yl)-2-oxo-2,3-dihydro-1,3-benzoxazole-5-
sulfonamide (5-06) could inhibit the formation of TAR29/cTAR29 duplex at concentrations that 
were markedly lower than those observed for the precursor structure 5 (Figure 1), thus 
indicating an increased ability to interfere with the NC-mediated annealing reaction. With an 
IC50 value of 20 ± 2 µM, compound 5-06 clearly appeared to be the most potent inhibitor in the 
analogue series (Table 1). Compounds 5-01, 5-02, 5-07, and 5-15 were ranked slightly below 
with IC50 values in the ~200 µM range. The remaining compounds displayed no detectable 
activity under the selected assay conditions, whereas one compound was not analyzed due to 
insufficient solubility (Table 1).  
 
ID 
NAME IC50 
(µM) 
ID 
NAME IC50 
(µM) 
5-01 170 ± 5 5-11 N.A. 
5-02 203 ± 8 5-12 N.A. 
5-03 N.D. 5-13 N.A. 
5-04 N.A. 5-14 N.A. 
5-05 N.A. 5-15 179 ± 7 
5-06 20 ± 2 5-16 N.A. 
5-07 163 ± 4 5-17 N.A. 
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5-08 N.A. 5-18 N.A. 
5-09 N.A. 5-19 N.A. 
5-10 N.A.   
Table 1. Ranking of analogues of compound 5 based on IC50 values 
determined by NAME assay. N.A.: not active. N.D.: not determined. 
 
 
 
Figure 3. NC-inhibitory activity of compound 5-06 assessed by using the Nucleocapsid Annealing Mediated 
Electrophoresis (NAME) assay [24]. Briefly, an 8 µM aliquot of NC(12-55) was pre-incubated with increasing 
concentrations of 5-06 at room temperature for 15 minutes. Each sample was then added with 1 µM each of TAR29 
and cTAR29, incubated at room temperature for 15 minutes, and then analyzed by non-denaturing polyacrylamide 
gel electrophoresis (see Materials and Methods for details).  
 
A closer examination of the results reveals that the most potent inhibitor 5-06, as well as 
the barely active compounds 5-01, 5-02, 5-07, and 5-15 share the benzoxazolinone scaffold, 
whereas all the benzimidazolinones displayed no detectable activity. Furthermore, the 5-06 
compound bears a 5-sulfonamide substitution that made it significantly more active than the 
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others in the benzoxazolinone series, which contain instead a 6-sulfonamide. Although these data 
are not sufficient to afford a comprehensive study of the structural-activity relationships, they 
provide important clues on the structural requirements characterizing efficient NC inhibitors 
among this series of compounds. 
 
Assessing the NC binding properties of benzoxazolinone analogues. The binding 
properties of 5-06 and other benzoxazolinone analogues were assessed by non-denaturing 
electrospray-ionization mass spectrometry (ESI-MS) to obtain valuable insights into the 
mechanism of action of this class of compounds. The experimental conditions were carefully 
optimized to enable the detection of intact NC containing coordinated zinc (see Materials and 
Methods). The analysis provided an experimental mass of 6488.91 u, which was in excellent 
agreement with a monoisotopic mass of 6488.91 u calculated for the full-length, 1-55 construct 
from the LAI strain containing two Zn(II) ions (see Figure S2 and Table S2 in Supplementary 
materials) [26]. The analysis was repeated upon addition of a ten-fold compound concentration, 
followed by 30 min equilibration at room temperature. Representative data obtained from 
samples treated with either compound 5-06, or its structural precursor 5, unambiguously revealed 
the formation of stable 1:1 complexes (Figure 4A and 4B, Table S2 in Supplementary 
materials), which corroborated the binding abilities of benzoxazolinone compounds predicted by 
our computational approaches. The non-covalent nature of the ligand interaction was confirmed 
by tandem MS analysis [27], which induced clean dissociation of the bound ligand to regenerate 
the mass of the initial unbound form of NC. 
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Figure 4. ESI-MS spectra of samples containing 5 µM NC and 10-fold molar concentrations of either 5 (A) or 5-06 
(B) (see Materials and Methods for details). For the sake of clarity, only the 5+ region is shown, which contained 
the base peak of each spectrum. The insets display the regions containing the ligand complexes, which were 
normalized to the same intensity scale to enable direct abundance comparisons. Additional signals corresponding to 
typical sodium, potassium and ammonium adducts were also detected with much lower intensities. 
 
For the sake of clarity, the regions corresponding to the 5+ charge states were plotted on 
the same intensity scale to enable a direct comparison of the abundances of the respective 
complexes (Figure 4, magnified insets). These data indicated that 5-06 was a significantly 
stronger binder than its 5 counterpart. In fact, when the partitioning between free and bound 
protein was calculated, we found that the analogue 5-06 displayed a fractional occupancy of 0.16 
± 0.04, as compared to 0.06 ± 0.02 obtained for the precursor 5. These results were consistent 
with a two to three-fold higher affinity of 5-06 for NC than displayed by compound 5, in 
excellent agreement with the greater inhibitory activity observed by the initial NAME assays.  
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Figure 5. ESI-MS spectrum of a sample containing 5 µM NC and 1-fold molar concentration of a ligand mixture 
containing 5, 5-01, 5-06, 5-07 and 5-15 (see Materials and Methods for details). The inset displays the isotopic 
distributions observed for the various complexes (A). A putative partitioning between complexes containing the 
nearly isobaric 5-01 (red) and 5-07 (blue) compounds was calculated by arbitrarily assigning equivalent binding 
affinities before fitting their combined intensities to the overall experimental distribution (black) (B). Additional 
signals corresponding to typical sodium, potassium and ammonium adducts were also detected with much lower 
intensities.  
 
 Binding competition assays were carried out to rank the relative binding affinities of the 
remaining benzoxazolinones. For example, the representative spectrum in Figure 5A was 
obtained from a single sample of NC substrate, which was treated with an equimolar mixture of 
5, 5-01, 5-06, 5-07, and 5-15. In agreement with their ability to compete for the NC binding 
pocket, signals corresponding to complexes containing any individual ligand were readily 
recognizable (Figure 5A, magnified inset), with the only exceptions consisting of those 
containing the nearly isobaric 5-01 and 5-07 compounds that possess very similar elemental 
compositions (Supplementary materials, Table S2). Comparing the respective signal intensities 
allowed for their relative affinities to be accurately assessed. When the affinities of the 5-01 and 
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5-07 compounds were arbitrarily considered as equivalent to enable the partitioning of their 
isotopic distributions (Figure 5B), the following scale of relative affinities was derived: 5-06 > 
5-01 ≈ 5-07 > 5-15 > 5. Significantly, this relative scale accurately matched the ranking of the 
inhibitory activities of NC annealing capabilities provided by the NAME experiments.   
 
Assessing the 5-06 benzoxazolinone inhibition of the nucleic acid destabilization and 
annealing activity of NC. The impromptu SAR analysis afforded by these experiments provided 
valuable information for the further optimization of these small molecule binders. The results not 
only corroborated our working hypothesis that benzoxazolinone derivatives may represent valid 
pharmacophores, but also indicated possible directions for the development of ligands with 
greater affinity for the NC hydrophobic pocket. To support these efforts, we decided to pursue 
further studies using a well-validated model system aimed to assess the mechanism of action of 
compound 5-06, by performing a destabilization assay that probes the ability of NC to destabilize 
the cTAR secondary structure [28]. Considering the critical dependence of this activity on the 
hydrophobic plateau of NC [29], the assay permits to evaluate the ability of the tested compound 
to compete with binding of unpaired guanines to this specific region of NC thus yielding 
complementary information to the direct binding observed by ESI-MS experiments. The 
destabilization assay employs an oligonucleotide mimicking a full-length cTAR domain and the 
NC(11-55) peptide from the MAL strain, different from the construct characteristic of the HIV-1 
LAI strain used in the NAME assay (see Materials and Methods). By testing the inhibitory 
activity using oligonucleotides and protein sequences from different viral isolates, we further 
challenge the validation of 5-06 as novel and potential NC inhibitor.  
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In the destabilization assay the cTAR was doubly labeled with a dye (Alexa488) and a 
quencher (Dabcyl) at its 5’- and 3’-end, respectively (cTAR55AD, see Materials and Methods). 
A properly folded conformation places the two dyes in very close proximity, which results in 
effective fluorescent quenching (Figure 6A, black line) [30], whereas denaturation of the hairpin 
structure, induced by the binding of NC, can restore emission of the Alexa488 dye (Figure 6A, 
red line) [6]. Based on these considerations, the fluorescent emission obtained from the pre-
formed cTAR55AD/NC(11-55) complex was monitored upon addition of increasing amounts of 
5-06. The results displayed a clear concentration-dependent decrease in fluorescence, which was 
consistent with the inhibition of the NC-induced fraying of the cTAR55AD structure (Figure 6A, 
inset). These data produced an IC50 of 210 ± 10 µM for the destabilization of nucleic acid 
secondary structure, a result comparable to previously reported small molecules inhibitor of NC 
[31]. 
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Figure 6. Inhibition of NC chaperone activity by 5-06 as monitored by fluorescence-based assays. Inhibition of the 
NC(11-55)-induced cTAR55 destabilization (A). Fluorescence spectra of cTAR55AD before (black) and after 
addition of NC(11-55) (red), and after addition of increasing concentrations of 5-06 to the cTAR55AD/NC mixture 
(from 25 to 500 µM, other colors). (Inset) Dose-response curve of the inhibition of NC(11-55)-induced cTAR55 
destabilization by 5-06. Inhibition of the NC(11-55)-promoted cTAR55AD/dTAR55 annealing (B). Annealing kinetic 
traces of cTAR55AD and dTAR55 after addition of NC(11-55) in the absence (black) and in the presence of 100 µM 
(red) and 200 µM (blue) of 5-06 (the kinetic curves were normalized). (Inset) Fluorescence spectra of cTAR55AD 
before (black) and after addition of NC(11-55) (red) and after completion of the annealing reaction with dTAR55 
(blue). (See Materials and Methods for details) 
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For the sake of consistency, we also performed annealing experiments after replacing the 
TAR29/cTAR29 system used by NAME assay with a dTAR55/cTAR55AD equivalent. The 
fluorescence kinetic assay employed a different experimental design aimed to optimize the 
measurement of an accurate kinetic rate, differently from the NAME assay meant to achieve 
stoichiometric binding between the two complementary sequences (see Materials and 
Methods). In this case, the deoxyribonucleotide dTAR55 was added at a 10-fold excess over its 
complementary cTAR55AD to ensure pseudo-first order conditions. An 8-fold excess of NC(11-
55) was added to activate the annealing reaction that was now monitored by recording the 
fluorescent emission of the Alexa488 dye (Figure 6B, blue spectrum). The curve generated by 
performing the reaction in the presence of increasing amounts of 5-06 revealed that 200 µM of 
compound decreased the annealing rate constant by 40% at the selected experimental conditions. 
The result appears in line with the activity found by the destabilization assay where the same 
compound concentration was found to inhibit the NC-induced cTAR destabilization by half.  
Taken together, all results support the mechanism of action hypothesized for the 
benzoxazole derivatives consisting in the non-covalent binding competing with unpaired guanine 
residues into the hydrophobic pocket of NC.  
 
Antiviral activity and cytotoxicity of compound 5-06. Two different phenotypic assays based on 
the reporter TZM-bl cell line were employed to assess the antiviral activity of compound 5-06. 
More specifically, the MonoCycle assay was used to evaluate the antiviral activity of the 
compound in the early stages of viral replication, whereas the BiCycle assay enabled evaluation 
of the inhibitory activity during the entire virus replication cycle (see Materials and Methods). 
The results provided IC50 values of 30.6 µM and 36.4 µM, respectively (Table 2 and Figure S4 
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in Supplementary materials), thus suggesting that most of the antiviral activity was likely exerted 
in the early phase of viral replication (i.e. from entry to integration).  
The general toxicity of 5-06 was evaluated on the TZM-bl reporter cell line as well as on 
the MT-2 T-cell line, which was employed in the first round of infection during the BiCycle 
assay (see Materials and Methods). 5-06 displayed a TD50 of 155 µM and 140 µM for the 
TZM-bl and MT-2 cell lines, respectively. Although the compound appeared not toxic at the 
inhibitory concentration, the latter appeared only four/five times lower compared to the toxic 
dose (Table 2 and Figure S4 in Supplementary materials). The results thus suggest that the 
antiviral activity should be improved in order to achieve a valuable inhibitor in an in vivo 
context. However, considering that the benzoxazolinone derivative previously described cmpd8 
possessed an antiviral activity that was significantly higher  (IC50 of 100 µM) [15], we believe 
that 5-06 represents an important improvement in this series of analogues and that novel 
chemical decoration to the shared scaffold may contribute to the development of more potent 
inhibitors. 
 
Assay IC50 (µM) TD50 (µM) SI 
MonoCycle 30.6 (20.6 - 45.2) 155* (111.9 – 304.5) 5.1 
BiCycle 36.4 (11.0 - 120.4) 140# (75.0 – 378.0) 3.8 
Table 2. Half-maximal inhibitory concentration (IC50), half-maximal toxic dose (TD50), and 
selectivity index (SI) observed for compound 5-06. 95% confidence level is reported between 
brackets. *Calculated in TZM-bl cells. #Calculated in MT-2 cells. 
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Structural determinants of benzoxazolinone-NC interactions. The results of these biophysical 
and biological determinations confirmed the validity of our virtual screening criteria by 
demonstrating that the selected compounds were indeed capable of interfering with NC 
chaperone activity. More significantly, they also provided direct insights into the structural 
determinants of NC binding and inhibition. With the goal of distilling these structural clues to 
inform further development, we submitted compound 5-06 to additional molecular modeling 
operations. The details of its molecular contacts with NC were contrasted with those of precursor 
5 to identify the possible reasons for the observed activity enhancement.  
Additional docking experiments were carried out for both compounds by employing 
greater resolution than the one used in the initial screening, while storing up to 10 different poses 
for visual inspection. The results showed that compound 5 interacted with the hydrophobic 
pocket by placing the 2-benzoxazolinone moiety in favorable position to establish π-π 
interactions with the aromatic side chain of Trp37, a key residue for NC function (Figure 7A). 
This binding mode was highly superimposable to that of guanine nucleobases in cognate nucleic 
acid substrates [16, 17], or that of the reference inhibitors cmpd3 and cmpd8 generated by NMR 
spectroscopy and computational modeling studies, respectively (Figure 2) [15, 19]. The models 
also showed that the 2-benzoxazolinone moiety could establish H-bond interactions with 
backbone atoms of Gly35, Met46, and Trp37 within the hydrophobic pocket (Figure 7A). An 
oxygen atom of the sulfonamide group interacted with the side chain of Gln45, while the other 
projected towards the solvent. The xylene moiety was docked in a conformation that allowed a 
cation-π interaction with the side chain of Arg32. Methyl groups did not appear to be involved in 
hydrophobic interactions, as one might expect. One of them was instead docked in a rather 
unfavorable, solvent-exposed conformation that may contribute to explain the lower affinity of 5 
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compared to 5-06. Accordingly, optimization of 5 should focus on the design of more suitable 
sulfonamides to interact with NC surface, as we did in this exercise by means of the substructure 
search.  
 
 
Figure 7. Benzoxazolinone-NC interactions predicted by docking and molecular dynamics (MD) simulations (see 
Materials and Methods). Interactions with the precursor 5 (A); the two putative binding modes afforded by 
compound 5-06 (B and C). Only the residues located within 5 Å from Trp37 are shown by using line representation. 
Only the residues making contact with the ligands (in cyan sticks representation) are labeled. Coordinated Zn(II) 
ions are showed as grey spheres, whereas H-bond interactions are marked as black dashed lines.  
 
In fact, experimental data indicated that replacing the xylene ring of 5 with an indazole 
ring in 5-06, as well as moving the sulfonamide group from position 6 to position 5 of the 2-
benzoxazolinone moiety, resulted in a significant increase of NC-inhibitory activity. Not 
surprisingly, these chemical modifications produced significant variations of the molecular 
contacts revealed by the respective models. Indeed, the docking models displayed two clearly 
distinctive binding modes, as showed in Figure 7B-C. The first was coherent with the one 
described above for compound 5, with the only exception consisting of the position assumed by 
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the indazole ring, which was not superimposable to the xylene ring of 5, but was placed instead 
in a solvent-accessible sub-pocket, where it established an H-bond with the backbone of Lys34 
(Figure 7B and Figure S3 in Supplementary materials). The second binding mode involved 
stacking of the indazole ring with the Trp37 of NC and formation of an H-bond contact with the 
Gly35 side chain (Figure 7C). In this case, the 2-benzoxazolinone moiety was oriented towards 
the solvent-exposed area and H-bonded to the side chain of Lys26. Notably, this change in 
position of the pharmacophore within the hydrophobic pocket seemed to be well tolerated, since 
most of the docking poses shared the indazole ring stacked on Trp37 and the 2-benzoxazolinone 
oriented towards the solvent in close proximity of Lys26. The preferential binding of the 
indazole ring with respect to the 2-benzoxazolinone moiety was consistent with theoretical 
estimations of binding affinity, which were completed according to different algorithms (Table 
S3 in Supplementary materials). These observations suggest that the alternative binding mode 
displayed by 5-06 may be the source of the significant gain of NC-inhibitory activity over 
precursor 5.  
This information opens new avenues for the rational design of optimized NC-inhibitor 
lead compounds. For instance, optimization of the binding mode of Figure 7A-B should not 
affect the 2-benzoxazolinone ring, which proved to be a suitable pharmacophore for NC 
inhibition, while trying to change the length, physicochemical features and pharmacophoric 
space in the sulfonamide portion. In addition, one may try to recycle the approach described in 
this work by screening in silico a library of indazole derivatives (Figure 7C) bearing different 
substituents, as well as to design rationally some indazoles with improved interactions with NC 
residues in the basic linker within the two zinc fingers. Results of this operations should lead to a 
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deeper understanding of indazole and 2-benzoxazolinone NCIs and related structure-activity 
relationships.  
 
CONCLUSIONS 
We implemented a concerted approach for the identification of novel NC-inhibitor chemotypes, 
which combined in silico computational techniques with biophysical and biological testing. With 
the goal of increasing the probability of capturing the structural determinants of ideal inhibitors, 
we expanded the chemical space screened in a previous study [15] by exploring a library that 
included over 3.5 million possible ligands. The selection process identified a number of 2-
benzoxazolinone analogues that shared the same scaffold with other compounds investigated 
earlier [15]. The fact that independent screens converged onto similar structural features suggests 
that this scaffold may indeed provide a solid foundation for developing a new class of NC 
inhibitors. The experimental evaluation of these analogues amounted to an impromptu SAR 
analysis that provided a possible roadmap for increasing the desired inhibitory properties.  
Our data unambiguously demonstrated that 2-benzoxazolinones are capable of binding to 
the hydrophobic pocket of NC and suppressing its nucleic acid chaperone activity. The binding 
experiments showed that all compounds in the series were capable of establishing non-covalent 
interactions with the protein, although with different affinities. No trace of apo-NC containing an 
incomplete complement of coordinated Zn(II) could be detected upon incubation with each 
compound, thus ruling out the possibility that ejection of zinc from the ZF domains might be the 
cause of the observed inhibitory effects. At the same time, the fact that the scale of relative 
binding affinities matched that of the inhibitory properties obtained by NAME suggests that the 
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mechanism of action is likely to involve direct competition between ligand and nucleic acid 
substrate for the hydrophobic pocket of NC. This observation was supported further by the 
ability of compound to inhibit the NC destabilization of cTAR structure, which is strictly 
dependent on the interaction of guanine residues with the zinc fingers domain of NC. The 
significant improvement of binding affinity between compounds 5 and 5-06 matched the 
increased ability to inhibit the annealing reaction mediated by NC. Taken together, these 
considerations indicate that the benzoxazolinone compounds must establish direct interactions 
with the protein, and in the process suppress its binding to putative nucleic acid substrates, to 
successfully prevent effective chaperoning from taking place. 
The results highlighted compound 5-06 as the most active analogue in the series, which 
afforded IC50 values in the low M range for both in vitro inhibition of annealing reactions and 
antiviral activity in HIV-infected cells. These values are clearly insufficient to warrant direct 
pharmacological applications. However, studying its specific interactions with NC provided very 
valuable insights for the possible design of more potent inhibitors. Docking simulations 
predicted two possible binding modes, with the first matching the interactions established by the 
less active precursor 5, and the second involving a different placement of the ligand within the 
hydrophobic pocket, which is unique for the more active 5-06. If these computational predictions 
were confirmed by adequate structural determinations, a possible strategy could involve 
introducing appropriate modifications of the 5-06 molecule to specifically favor the more active 
binding mode. Based on this information, we plan on pursuing a systematic SAR study aimed at 
stabilizing the active binding mode and increasing the putative pharmacophoric properties of 
compound 5-06. 
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MATERIALS AND METHODS 
Virtual screening. The structures of NC in complex with DNA and RNA previously refined 
through molecular dynamics and density functional theory DFT study [18], as well as the NMR 
structure of the NC in complex with a reference small molecule inhibitor [19], were used as rigid 
receptors in molecular modelling simulations. Molecular docking was performed with FRED, 
version 3.0.1, from OpenEye (Santa Fe, NM) scientific software [20, 21]. Rescoring of docking 
poses was carried out with the chemscore function [32], the fred_rescore utility, and the 
XSCORE program [33]. Ligand conformational analysis was performed with OMEGA, version 
2.5.1.4, from OpenEye scientific software allowing the generation of up to 400 conformers [34, 
35]. Scaffold extraction from the ZINC database was performed by the FILTER algorithm 
(OpenEye, Santa Fe, NM) [34, 35]. 
 
Compounds, oligonucleotides, and NC protein preparation. Selected compounds identified by 
the screening process were purchased from MolPort (Riga, LV), dissolved in pure DMSO and 
stored in a freezer at -20°C. All solutions were freshly prepared by diluting the initial DMSO 
stock into water to the desired concentration. The following oligonucleotide constructs were 
employed in the study: TAR29, 5’-GGC AGA UCU GAG CCU GGG AGC UCU CUG CC-3’ 
(RNA); cTAR29, 5’-GGC AGA GAG CTC CCA GGC TCA GAT CTG CC-3’(DNA); cTAR55, 
5’-GGT TCC TTG CTA GCC AGA GAG CTC CCG GGC TCG ACC TGG TCT AAC AAG 
AGA GAC C-3’ (DNA); dTAR55, 5’-GGT CTC TCT TGT TAG ACC AGG TCG AGC CCG 
GGA GCT CTC TGG CTA GCA AGG AAC C-3’ (DNA). TAR29 was purchased from 
Metabion (Steinkirchen, D), cTAR29 from Eurogenetec (Seraing, B), dTAR55 and cTAR55 
from IBA GmbH Nucleic Acids Product Supply (Göttingen, D), and used without further 
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purifications. The cTAR55AD sequence was labeled at the 5’-terminus with an Alexa488 
fluorophore via an amino-linker with a six carbon spacer arm, and at the 3’-terminus with 4-(4’-
dimethylaminophenylazo) benzoic acid (Dabcyl) by using a special solid support with the dye 
already attached. TAR29 and cTAR29 correspond to the top half hairpin structure of the trans-
activation response element from HIV-1 LAI strain, whereas cTAR55 and dTAR55 are from the 
HIV-1 MAL strain. The NC(12-55) (TVKCF NCGKE GHIAK NCRAP RKKGC WKCGK 
EGHQM KDCTE RQAN) corresponding to the NC sequence from LAI strain lacking the first 
eleven residues was synthetized by EspIkem Peptides (Polo scientifico e tecnologico di Sesto 
Fiorentino, Firenze, IT) and was stored in the freezer at -20°C in Tris buffer (Tris 10 mM, pH 
7.5). The NC(11-55) peptide (KNVKC FNCGK EGHTA RNCRA PRKKG CWKCG KEGHQ 
MKDCT ERQAN), encompassing the two zinc fingers of NC from the MAL strain, was 
synthesized and purified as described previously and stored lyophilized [36]. Before use, 2.5 
equivalent of ZnSO4 was added to NC(11-55) dissolved in water, and the pH was raised by 
addition of buffer. The 55-residue, full-length recombinant NC (IQKGN FRNQR KTVKC 
FNCGK EGHIA KNCRA PRKKG CWKCG KEGHQ MKDCT ERQAN) was expressed in E. 
coli, purified by ion-exchange and size exclusion chromatography, as reported elsewhere [27], 
and stored in ammonium acetate 100 mM in the freezer at -20°C. An extinction coefficient of 
5700 M-1cm-1 and 6410 M-1cm-1 at 280 nm were used to determine the concentration of the NC 
peptides and full-length NC respectively. 
 
In vitro evaluation of NC inhibitory activity. Selected compounds were tested for their ability to 
inhibit the chaperoning activity of NC by means of the Nucleocapsid Annealing Mediated 
Electrophoresis (NAME) assay [24]. This assay is based on the NC-mediated annealing of 
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constructs mimicking the HIV-1 trans-activation response element (TAR) RNA and its 
complementary DNA (cTAR). The shorter version of NC(12-55) from the LAI strain was used 
instead of the full-length counterpart to limit unspecific aggregation of nucleic acids [37, 38]. 
The TAR29 and cTAR29 constructs were folded separately in Tris buffer (Tris 25 mM, NaCl 30 
mM, Mg(ClO4)2 0.2 mM, pH 7.5) by first heating for 5 min at 95°C, and then slowly cooling 
down to room temperature to produce the desired monomeric hairpins. Annealing reactions were 
carried by mixing equimolar amounts of TAR29 and cTAR29 (final 1 µM each) with an 8-fold 
amount (final 8 M) of NC(12-55), and then incubating at room temperature for 15 min. Control 
experiments were carried out by heat-refolding an equimolar mixture of TAR29 and cTAR29 to 
obtain the TAR29/cTAR29 duplex in the absence of chaperone. Inhibitory activity was 
determined by pre-incubating NC(12-55) with increasing compound final concentrations (as 
indicated in the figure) at room temperature for 15 min, before adding the solution to the above 
mixture of TAR29 and cTAR29. We made sure that the concentration of DMSO coming from 
the compound stocks was the same in all reaction wells and did not exceed a 2% v/v 
concentration. The annealing reactions were stopped by adding gel-loading buffer (100 mM Tris, 
4 mM EDTA, 2% SDS, 50% glycerol, 0.05% bromophenol blue, pH 7.5), which induced 
denaturation of the zinc-finger structure without causing dissociation of the nucleic acid duplex. 
The reaction mixtures were loaded on a 12% polyacrylamide gel in TBE buffer (Tris-Borate 89 
mM, EDTA 2 mM) and analyzed at 200 V for 3h. Gel was stained with SYBR Green II and 
visualized on a Geliance 600 Imaging System (Perkin Elmer, Waltham, MA, USA). Band 
quantification was performed by using the GeneSnap software (SynGene, Cambridge, UK). The 
percentage of inhibition of annealing activity (𝐼𝑛ℎ%) was obtained by using as a baseline the 
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intensity of the band corresponding to the TAR29/cTAR29 duplex, which was observed in the 
absence of inhibitor. Actual values were calculated according to the dose response equation (1): 
𝐼𝑛ℎ% = 𝐴1 +
(𝐴2−𝐴1)
1+10(log(𝐼𝐶50)−log⁡( 𝐶)×⁡𝑝)
 (1) 
in which A1 and A2 represent the inhibition observed in the absence and presence of saturating 
concentrations of inhibitor, respectively. C corresponds to the concentration of inhibitor, and p 
denotes the Hill coefficient. The half-maximal inhibitory concentration (IC50) was calculated by 
using Prism 5.0 (GraphPad, La Jolla, CA, USA) to obtain the best possible fit to triplicate 
experimental data. 
 
Evaluation of binding properties. The stoichiometry and strength of the binding interactions 
between NC and the various compounds were evaluated by using electrospray-ionization mass 
spectrometry (ESI-MS) under non-denaturing conditions. The detection of intact non-covalent 
complexes, like those formed by these ligand-NC systems, can be achieved by appropriately 
tuning the ion source conditions to minimize the desolvation energy [39]. This type of analysis 
can reveal the accurate partitioning between any free and bound species in solution, which can 
provide the binding constant of a given complex [40]. Moreover, performing experiments in 
which a mixture of ligand must compete simultaneously for the same substrate can effectively 
provide a relative scale of binding affinities by comparing the signal intensities of the complexes 
detected in the same spectrum [41]. In a typical experiment, a final 5 µM sample of NC was 
mixed with 50 µM concentration of compound in 150 mM ammonium acetate at pH 7.5. Binding 
competition experiments instead, included 5 µM concentration of each test compound in the 
same solvent. Full-scan ESI-MS spectra were acquired after 30 min incubation at room 
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temperature to allow for the establishment of the binding equilibrium. Tandem MS analysis was 
performed to verify the reversible nature of the protein-ligand interactions. Protein fractional 
occupancy was calculated according to equation (2):  
𝑓𝑏 =
∑(𝐼𝑁𝐶+𝐿 𝑧⁄ )
∑[(𝐼𝑁𝐶+𝐿+𝐼𝑁𝐶) 𝑧⁄ ]
 (2) 
in which fb represents the fraction of NC bound by the ligand (L), z is the charge state of the 
specie, INC+L and INC are the areas under the curve of the signal corresponding to protein-ligand 
complexes and free protein, respectively. All the detected charge states were included in the 
calculation to minimize any quantification bias [42]. 
All determinations were conducted in positive ion mode on a Thermo Fisher Scientific 
LTQ-Orbitrap Velos mass spectrometer. Typically, 6 µL samples were sprayed in nanoflow ESI 
mode by using quartz emitters produced in house. Source conditions were set to maximize the 
detection of intact holo-NC (containing full complement of coordinated Zn(II) ions) [26], which 
were typical achieved at an ionizing voltage of 0.8 kV, a desolvation voltage between 0 and 50 
V, and a source temperature of 200°C. Data were analyzed by using Xcalibur 2.1 software 
(Thermo Fisher Scientific). 
 
Nucleic acid destabilization assay. The cTAR construct was employed to assess the ability of 
selected compounds to inhibit the destabilizing effects of NC on nucleic acid secondary 
structure. The assay required labeling the ends of the construct and then monitoring of the 
fraying in the hairpin’s stem by fluorescence spectroscopy. Baseline destabilization activity was 
determined by mixing cTAR55AD and NC(11-55) peptide (final 100 and 1000 nM 
concentrations, respectively) in Tris buffer (Tris 25 mM, NaCl 30 mM, MgCl2 0.2 mM, pH 7.5), 
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and then recording the corresponding fluorescence spectra at 20°C and 480 nm excitation on a 
Fluoromax 3 spectrofluorimeter (Horiba Jobin-Yvon, Longjumeau, France) equipped with a 
thermostated cell compartment. To assess the inhibitory activity of compound 5-06, the same 
experiments were conducted adding increasing concentrations of 5-06 to the pre-formed 
cTAR55AD-NC(11-55) complex. The data were corrected for dilution, buffer fluorescence, 
intrinsic fluorescence of the tested compound, and the wavelength-dependent response of the 
optics. Absorption spectra were recorded with a Cary 4000 spectrophotometer (Agilent, Santa 
Clara, CA, USA). In this case, the percentage of inhibition (𝐼𝑛ℎ%) was calculated at each 
concentration according to equation (3): 
𝐼𝑛ℎ% =
𝐼(𝑐𝑇𝐴𝑅+𝑁𝐶)−𝐼(𝑐𝑇𝐴𝑅+𝑁𝐶+𝑰𝑵)
𝐼(𝑐𝑇𝐴𝑅+𝑁𝐶)−𝐼(𝑐𝑇𝐴𝑅)
× 100 (3) 
in which I(cTAR), I(cTAR+ NC), and I(cTAR+NC+IN) correspond to the fluorescence intensity of 
cTAR55AD alone, cTAR55AD in the presence of NC protein, and cTAR55AD in the presence of 
both NC and inhibitor (IN), respectively. The dose response equation (1) and the fitting 
algorithm of Origin 8.6 (Northampton, MA, USA) were then employed to process triplicate 
experimental data and obtain the desired IC50 value.  
 
Annealing kinetic assay. The annealing of dTAR (deoxy-ribonucleotide TAR) and cTAR 
(complementary deoxy-ribonucleotide TAR) constructs was employed to assess the inhibitory 
effect of compound 5-06 on the chaperone properties of NC. The assay was set up to report on 
the kinetics of the annealing reaction by monitoring the fluorescence emitted by specific 
chromophores placed at the ends of the hairpin constructs. More specifically, the cTAR55AD 
sequence was labeled with Alexa488 dye and Dabcyl quencher at the 5’- and 3’-ends, 
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respectively (see above), in such a way as to achieve effective quenching when folded into an 
intact hairpin structure, but to induce proper emission when involved in a duplex complex with 
the complementary dTAR55. The kinetics analysis was carried out under pseudo first-order 
conditions by using a 10-fold excess of dTAR55 versus cTAR55AD (i.e., final 100 nM and 10 nM 
concentrations, respectively) in Tris buffer (Tris 25 mM, NaCl 30 mM, MgCl2 0.2 mM, pH 7.5). 
The nucleic acid samples were premixed separately with an 8-fold molar excess of NC(11-55) 
peptide, then mixed in equal volumes to initiate the annealing reaction. The excitation and 
emission wavelengths afforded by Alexa488 (i.e., 480 and 519 nm, respectively) were employed 
to monitor the reaction, which was carried out in the cell compartment of a Fluoromax 3 
spectrofluorimeter (Horiba Jobin-Yvon, Kyoto, Japan) thermostated at 20°C. Upon establishing 
the baseline kinetics for the cTAR55AD/dTAR55 in presence of NC(11-55), in the absence of 
ligand, compound 5-06 was tested by adding increasing concentrations to the initial 
dTAR55/NC(11-55) mixture. An equivalent volume of DMSO was added to the corresponding 
cTAR55AD/NC(11-55) mixture to cancel out any possible bias introduced by the solvent in the 
stocks. In all experiments, the amount of DMSO was kept at 1% v/v concentration. The kinetic 
rate constant of the annealing reaction was calculated by non-linear fitting of the fluorescence 
trace over time to a mono-exponential equation (4) [43]: 
𝐼(𝑡) = ⁡ 𝐼𝐹 − (𝐼𝐹 −⁡𝐼0)𝑒
−𝑘𝑜𝑏𝑠(𝑡−𝑡0) (4) 
in which t0 is the dead time, kobs is the observed kinetic rate constant, I0 is the fluorescence 
intensity of the cTAR55AD/NC(11-55) mixture before addition of the dTAR55/NC(11-
55)/compound mixture, and IF is the fluorescence intensity after completion of the annealing 
reaction. The data were analyzed by using the Origin 8.6 software, based on non-linear, least-
square methods and the Levenberg-Marquardt algorithm. 
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Evaluation of antiviral activity. Two complementary assays were employed to assess the effects 
of ligands during a single or two cycles of cell infection (i.e., Monocycle and BiCycle assay, 
respectively) [44]. In the former, TZM-bl cells were seeded in a 96-well plate at a concentration 
of 30,000/well. Each well was infected with a stock of NL4-3 strain in the presence of serial 
five-fold dilutions of compound 5-06 ranging from 5 nM to 400 µM concentration, and 
incubated at 37°C in 5% atmosphere of CO2. Two days later, the cells in each well were lysed by 
adding 40 µL of Glo Lysis Buffer (Promega, Madison, WI, USA) for 5 min. A 40 µL aliquot of 
Bright-Glo Luciferase Reagent (Promega) was added to each well to enable analysis by a Glo-
Max Multi Detection System (Promega), which provided a count of relative luminescence units 
(RLU). Prism 6.0 (GraphPad) was used to process the RLU value from each well to calculate the 
IC50 and the interval corresponding to a 95% confidence level (CI95%) afforded by the test 
compound. In the BiCycle assay format, MT-2 cells were seeded in a 96-well plate at a 
concentration of 50,000 cells/well and infected with NL4-3 strain in presence of five-fold 
dilutions of the compound 5-06 ranging from 5 nM to 400 µM concentration. After a 72-hours 
incubation at 37°C in 5% CO2, a 50 µL aliquot of supernatant from each well, which containing 
the virus produced in the first round of infection, was used to infect TZM-bl cells seeded in a 96-
plate well at a concentration of 30,000 cells/well. After a 48-hours incubation at 37°C in 5% 
CO2, the RLUs were counted and processed as described above. Both cell lines and the NL4-3 
strain were obtained from the NIH AIDS Reagent Program (ARP) 
(https://www.aidsreagent.org/). 
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Evaluation of cytotoxicity. Cellular toxicity was assessed through the CellTiter-Glo 2.0 Assay 
(Promega), which relies on the quantification of adenosine triphosphate (ATP) in the cell as a 
marker of viability. In this case, MT-2 cells were seeded at a concentration of 50,000 cells/well 
in the presence of serial five-fold dilutions of compound 5-06 ranging from 6 nM to 500 µM 
concentration, and then incubated for 72 hours at 37°C in 5% CO2. After incubation, the plate 
was centrifuged and culture medium was replaced with 100 µL of CellTiter-Glo Reagent 
(Promega). TZM-bl cells were seeded at a concentration of 15,000 cells/well in presence of serial 
two-fold dilution of compound 5-06 ranging from 3.1 µM to 400 µM, and incubated for 48 hours 
at 37°C in 5% CO2. After incubation, the medium was replaced with 100 µL of CellTiter-Glo 
Reagent (Promega). For both cell lines, after a further 10-min incubation with orbital shacking, 
RLUs were counted and processed as described above for evaluation of the antiviral activity. The 
Toxic Dose 50% (TD50) was calculated by normalizing RLUs values to those obtained from 
untreated cells, which provided the baseline corresponding to 100% viability. 
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